Free Trial

ADMA Biologics (NASDAQ:ADMA) Hits New 1-Year High at $10.87

ADMA Biologics logo with Medical background

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report)'s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $10.87 and last traded at $10.85, with a volume of 1350696 shares. The stock had previously closed at $10.44.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ADMA. HC Wainwright lifted their target price on ADMA Biologics from $7.50 to $10.00 and gave the stock a "buy" rating in a report on Friday, May 10th. Raymond James boosted their price objective on ADMA Biologics from $8.00 to $10.00 and gave the company a "strong-buy" rating in a report on Friday, May 10th. Cantor Fitzgerald boosted their price objective on ADMA Biologics from $8.00 to $10.00 and gave the company an "overweight" rating in a report on Friday, May 10th. Finally, Mizuho boosted their price objective on ADMA Biologics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday, May 10th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from, the stock presently has an average rating of "Buy" and a consensus price target of $10.50.

Check Out Our Latest Analysis on ADMA Biologics

ADMA Biologics Trading Up 1.7 %

The company has a market cap of $2.46 billion, a PE ratio of -531.00 and a beta of 0.48. The stock has a fifty day moving average of $8.34 and a 200-day moving average of $6.32. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.86 and a current ratio of 5.21.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.03. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The business had revenue of $81.90 million during the quarter, compared to analysts' expectations of $77.28 million. During the same period in the prior year, the business earned ($0.03) EPS. The business's revenue for the quarter was up 43.9% compared to the same quarter last year. Sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other ADMA Biologics news, CEO Adam S. Grossman sold 100,000 shares of the company's stock in a transaction on Friday, June 14th. The stock was sold at an average price of $10.72, for a total value of $1,072,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,081,475 shares in the company, valued at approximately $22,313,412. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.70% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ADMA. Mesirow Institutional Investment Management Inc. bought a new position in shares of ADMA Biologics in the 1st quarter worth $17,221,000. Rice Hall James & Associates LLC acquired a new position in ADMA Biologics during the 1st quarter valued at about $7,963,000. Charles Schwab Investment Management Inc. increased its position in ADMA Biologics by 182.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,609,346 shares of the biotechnology company's stock valued at $5,761,000 after buying an additional 1,039,893 shares in the last quarter. Walleye Capital LLC acquired a new position in ADMA Biologics during the 3rd quarter valued at about $3,318,000. Finally, Peregrine Capital Management LLC acquired a new position in ADMA Biologics during the 4th quarter valued at about $3,991,000. 75.68% of the stock is owned by institutional investors.

About ADMA Biologics

(Get Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Articles

Should you invest $1,000 in ADMA Biologics right now?

Before you consider ADMA Biologics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.

While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines